Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and National Institutes of Health's (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have formed a public-private partnership to support the work of Drug Induced Liver Injury Network (DILIN).
Subscribe to our email newsletter
DILIN is a group working to bring together essential scientific and financial resources to better understand drug-induced liver injury as well as effective screening, diagnostic and treatment options.
Under the terms of the partnership, AstraZeneca will join other companies to provide funding for the project. AstraZeneca will also have a seat on a DILI scientific board, a group convened by FNIH that includes representatives of all the partners in this endeavor, to provide expertise and input on scientific and technical matters.
Joachim Forsgren, VP and global head of patient safety at AstraZeneca, said: “The safety of patients who need drugs to treat many different kinds of conditions and illnesses is paramount in both developing new medicines and safely and effectively using products currently on the market. We want to play our part in furthering this critical work, which will provide valuable insight to all those engaged in the research and development of drugs.”
Charles Sanders, chairman of the Foundation for NIH, said: “We welcome the support of AstraZeneca’s underlying commitment to work with the Foundation for NIH, and NIH, as we pursue advances in research and potential treatment options for drug-induced liver injury. Bringing together a team of experts in a collaborative environment is essential to this project’s overall success.”